Related Experiment Videos
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease
M J Järvisalo1, J O Toikka, T Vasankari
1Department of Clinical Physiology, Turku University Central Hospital, Turku, Finland.
Insights
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, improve vascular endothelial function in patients with coronary artery disease. This benefit appears independent of cholesterol-lowering effects, suggesting broader cardiovascular protective potential.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) are known for their cholesterol-lowering effects.
- Emerging evidence suggests statins may improve vascular endothelial function independently of lipid reduction.
Purpose of the Study:
- To investigate whether statin therapy enhances vascular endothelial function in patients with coronary artery disease, irrespective of their lipid levels.
- To determine if statin use is a predictor of improved endothelial function.
Main Methods:
- A comparative study involving two groups of coronary artery disease patients matched for age, blood pressure, and lipid levels.
- High-resolution ultrasound was used to measure flow-mediated dilation (endothelium-dependent) and nitrate-mediated dilation (smooth muscle-dependent) in the brachial artery.
Main Results:
- Patients on statin therapy exhibited significantly higher flow-mediated dilation (FMD) compared to those not on statins (4.3% vs. 2.6%, P<0.05).
- Statin use was identified as the sole significant predictor of FMD in a multivariate regression model.
- A positive trend was observed between FMD and statin dosage.
Conclusions:
- Statin therapy is associated with improved vascular endothelial function in patients with established coronary artery disease.
- These findings support the hypothesis that statins exert beneficial effects on endothelial function independent of their lipid-lowering properties.
- Statin-induced endothelial benefits may contribute to secondary prevention of coronary artery disease, potentially regardless of baseline cholesterol concentrations.
Abstract:
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (statins) may enhance vascular endothelial function independent of their cholesterol lowering effect. To test this hypothesis, we surveyed two groups of patients (age 55+/-7, mean+/-SD) with coronary artery disease that were matched for age, blood pressure and serum lipid levels. Group 1 comprised 23 men without lipid-lowering medication and Group 2 included 22 patients with ongoing HMG CoA reductase inhibitor medication. Flow-mediated (endothelium-dependent) arterial dilatation (FMD) and nitrate-mediated (smooth muscle dependent) dilatation (NMD) were measured in the brachial artery using high resolution ultrasound. FMD was considerably higher in group 2 (4.3+/-2.6 vs. 2.6+/-2.8%; P<0.05). In multivariate regression model, statin use was the only significant (P<0.05) predictor of FMD. In all subjects, FMD correlated with statin dose (P<0.05 for trend). NMD was non-significantly higher in group 2 (11.4+/-5.0 vs. 9.0+/-4.2%, P=0. 08). We conclude that patients with established coronary artery disease on HMG CoA reductase inhibitor therapy have better vascular endothelial function than similar patients without the medication. These data provide further support for the idea that HMG CoA reductase inhibitors enhance endothelial function independent of their lipid-lowering effects. This may suggest that these drugs could be beneficial in secondary prevention of coronary artery disease regardless of the serum cholesterol concentration.